Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Gallbladder Neoplasms 1

Interventions

Gemcitabine 26Capecitabine 16Oxaliplatin 14Fluorouracil 13Cisplatin 12Leucovorin 9pembrolizumab 5Erlotinib Hydrochloride 5Bevacizumab 5durvalumab 4Trastuzumab 4Specimen Handling 4Sorafenib 4Magnetic Resonance Spectroscopy 4130-nm albumin-bound paclitaxel 4trifluridine tipiracil drug combination 3Lapatinib 3Irinotecan 3Carboplatin 3Biopsy 3tremelimumab 2toripalimab 2regorafenib 2lenvatinib 2dehydroftorafur 2cobimetinib 2atezolizumab 2anlotinib 2Nivolumab 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gallbladder Neoplasms × Mutation × Clear all
NCT03772132 2018-12-11

Chemothetapy FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Shanghai Jiao Tong University School of Medicine

Phase 2 Unknown
100 enrolled
Gastrointestinal

Gallbladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡